All you need to get started with ETF selection and analysis. Create your account now →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

›ETF Issuers›Franklin Templeton›HELX

HELX

Franklin Genomic Advancements ETF

Active ETF Equity Theme: BioTech & Genomics

Not rated

The HELX Exchange Traded Fund (ETF) is provided by Franklin Templeton. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.

$39.71

+$0.22 (+0.56%) yesterday

1:30 PM 07/15/26 Closed

1D price range

$39.54$39.71

52W price range

$27.00$41.16

YTD Perf.

+10.69%

YTD Flows

Annualized volatility

Fund AuM

€26M

Share class AuM

€26M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US35473P5200

TER

0.5%

Inception date

2/25/2020

Issuer

Franklin Templeton

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
CURE VanEck Genomics and Healthcare Innovators UCITS ETF	-5.37%
EKG First Trust Nasdaq Lux Digital Health Solutions ETF	-1.97%
DOCG L&G Healthcare Technology & Innovation UCITS ETF	-2.38%
HTEC Robo Global Healthcare Technology and Innovation ETF	-2.24%
XHE State Street SPDR S&P Health Care Equipment ETF	-3.07%
FBT First Trust NYSE Arca Biotechnology Index Fund ETF	-4.06%
FBT First Trust NYSE Arca Biotechnology ETF	-4.85%
BBP Virtus LifeSci Biotech Products ETF	-1.29%
HEAL Global X Telemedicine & Digital Health ETF	-3.87%
FBT First Trust NYSE Arca Biotechnology UCITS ETF	-4.06%
PBE Invesco Dynamic Biotechnology & Genome ETF	-4.30%
WDNA WisdomTree BioRevolution UCITS ETF	+0.04%
GNOM Global X Genomics & Biotechnology ETF	-4.08%
GNOG Global X Genomics & Biotechnology UCITS ETF	-4.07%
WDNA WisdomTree BioRevolution Fund	-5.79%

API

PerformanceDec 31, 2025 - Jul 10, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 05/31/26

Healthcare

96.45%

Non-Energy Materials

2.51%

Technology

1.04%

Latest HELX news

No content available for this fund

FAQ about HELX

HELX is a Active ETF. This ETF provides exposure to Other Global Equities.

HELX carries a total expense ratio (TER) of 0.5%, indicating the annual cost for holding the fund.

HELX was introduced to the market on February 25, 2020. It trades on United States

Franklin Genomic Advancements ETF, HELX, is provided by Franklin Templeton. Learn more about Franklin Templeton here.

HELX oversees €26M in assets as of July 10, 2026.

HELX follows a distributing dividend policy, meaning it pays out income to investors.

As of May 31, 2026, HELX has significant geographic allocations in USA, United Kingdom and Republic of Korea.

As of May 31, 2026, HELX focuses largely on Healthcare, Non-Energy Materials and Technology.

As of May 31, 2026, HELX holds 60 positions in its portfolio, with 58.65% of assets concentrated in its top 15 holdings.

As of May 31, 2026, HELX top three holdings include Guardant Health, Inc., Natera, Inc. and Krystal Biotech, Inc..

The base currency of HELX is USD.

Top 10 holdings

Data as of 05/31/26

Guardant Health, Inc.

9.12%

Natera, Inc.

6.58%

Krystal Biotech, Inc.

6.15%

United Therapeutics Corp.

4.35%

Ligand Pharmaceuticals, Inc.

4.06%

BridgeBio Pharma, Inc.

3.68%

AstraZeneca PLC

3.12%

Adaptive Biotechnologies Corp.

3.04%

Eli Lilly & Co.

3.01%

Insmed, Inc.

2.87%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Don’t Miss a Move in the ETF Market

Franklin Genomic Advancements ETF

FAQ about HELX

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US